Forskolin

Catalog No.S2449 Synonyms: Coleonol

Forskolin Chemical Structure

Molecular Weight(MW): 410.5

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 110 In stock
USD 270 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 25 Publications

Purity & Quality Control

Choose Selective cAMP Inhibitors

Biological Activity

Description Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.
Targets
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
In vitro

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 NX\5bmlJTnWwY4Tpc44hSXO|YYm= NID5RXIyOCEQvF2= NIP1fHQ3KGh? M2[2WYlv[3KnYYPld{BxcG:|cHjvdplt[XSrb36gc4Yhd3[ncnX4dJJme3OnZDDLUGhNOyCjdDDTOFM{ M1[1XFI3PDN3NEm4
Mo-DCs NHLmc21HfW6ldHnvckBCe3OjeR?= NWn0[lZ5PTBizszN MnXGNlTjiImq MYrwdo9ud3SnczDJUE0zOyCycn;keYN1cW:wIHnuJJRp\SC|dYDldo5ifGGwdDDv[kB7gW2xc3HuJJN1cW23bHH0[YQhVW9vRFPzxsA> NXPWVmJbOjZ2MUK5OFg>
RBMECs  NFnXOm9HfW6ldHnvckBCe3OjeR?= MkLIOeKh|ryP M4jkSFHDqGh? MWricI9kc3NidHjlJHJi[zFiaX7hZ5RqfmG2aX;uJIlv\HWlZXSgZpkhTU2DUD3JTS=> M{myVFI3OzV6MEO5
INA-6 MlSxR4VtdCCYaXHibYxqfHliQYPzZZk> MkO0NE0yODBizszN M13nOFcz6oDLaB?= MX3pcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= M2rGWFI3OzB4NkK0
OPM-2 M{fXUWNmdGxiVnnhZoltcXS7IFHzd4F6 NGfrZXExNTFyMDFOwG0> M1LufVcz6oDLaB?= NUTF[lNWcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> MV:yOlMxPjZ{NB?=
U266 MVXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoO5NE0yODBizszN NWHocotbPzMkgJno M1;2WIlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 M1zrZ|I3OzB4NkK0
H929 MlO0R4VtdCCYaXHibYxqfHliQYPzZZk> MljFNE0yODBizszN NF3YU3M4OuLCiXi= MWnpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= MUKyOlMxPjZ{NB?=
RPMI 8226 MkDVR4VtdCCYaXHibYxqfHliQYPzZZk> M2OzZVAuOTByIN88US=> NX;0cHlVPzMkgJno NIHyWFZqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> M4DT[FI3OzB4NkK0
MDCK  M{TR[WZ2dmO2aX;uJGF{e2G7 M4XMdlExKML3TR?= M37MXFI1KGh? MWHEUXNQ NIfleoV2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCWR1[t{tIyKGGwZDDDWGdHyqB? M4eyTlI3OjB{M{Wy
MDCK  NXjD[VVyTnWwY4Tpc44hSXO|YYm= MX2xNEDDvU1? NULreGhNOjRiaB?= MUfEUXNQ MYjpcohq[mm2czD0bIUhcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gSm4h[2G3c3XkJIJ6KFSJRj5OtlE> MlL6NlYzODJ|NUK=
Spinal cords  NFXwfopHfW6ldHnvckBCe3OjeR?= MX6xxsDPxE1? M{C0WVMxKG2rbh?= NGS2PY1{fGmvdXzheIV{KGODTWCgcIV3\Wy| Mne1NlYyOjZ7Mk[=
BeWo  M{DQUmZ2dmO2aX;uJGF{e2G7 M2\CNFI26oDLzszN M2KxeFI1NzR6L{eyJIg> MUjs[YFleyC2bzDhckBqdmO{ZXHz[UBqdiC2aHWg[ZhxemW|c3nvckBw\iCxdHjldkBnfXOrb36gcYFzc2W{cx?= MUCyOlA2OzV2OR?=
bovine oocytes MkD0SpVv[3Srb36gRZN{[Xl? MkTaNVAxyqEQvF2= NWPySm1xOTMEoHi= MXrpcohq[mm2czD0bIUh\W[oZXP0JI9nKE6SUFGgZY5lN2:{IF7QVGMhfG9ic4TpcZVt[XSnIILld5VueHSrb36gc4YhdWWrb4Ppdy=> MoLKNlYxPTF4MUG=
Caco-2  NUCxSJFyTnWwY4Tpc44hSXO|YYm= NVPSWHRTOC5zL{GvNVAh|ryP MUOyNOKhdWmw NFvITHZqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4hcW62cnHj[YxtfWyjcjDjRW1RKGyndnXsdy=> MUCyOlA1QTFyMh?=
Caco-2  NYW4XGZ6TnWwY4Tpc44hSXO|YYm= MUWwMlEwOS9zMDFOwG0> NYfmVmRiOjRiaB?= NXnvOHJIcW6lcnXhd4V{KE2UUEKgdJJwfGWrbjDs[ZZmdA>? MVSyOlA1QTFyMh?=
AML-12  NYDie|BoTnWwY4Tpc44hSXO|YYm= MlPLNlAh|ryP NF;FUFQ{KGh? MX31dJJm\3WuYYTld{B1cGVicHjvd5Bpd3K7bHH0bY9vKGyndnXsd{BifCCWaIKtOFEyKGGwZDDT[ZIuPDl| M33UVlI3ODR6OUi1
AML-12  MVjGeY5kfGmxbjDBd5NigQ>? NF75WJMzOCEQvF2= NX7rSGFmOS16IHi= M2L3[Ilv[3KnYYPld{BodHWlb4PlJJBzd2S3Y4Tpc44> NH\YeGIzPjB2OEm4OS=>
AML-12  MWPGeY5kfGmxbjDBd5NigQ>? NXnqT4x5OjBizszN NHnjfYk{KGh? MYj1dE1z\We3bHH0[ZPDqFCpY{HhMOKhWGWyY3usJIFv\MLiR{\wZ:KhdVKQQTDs[ZZmdHN? M1;ocVI3ODR6OUi1
AML-12  M{fJ[2Z2dmO2aX;uJGF{e2G7 MUmyNEDPxE1? MlL4N{Bp NXXKOZhJcW6mdXPld{B1cGViZHXwbI9{eGixconsZZRqd25ib3[gR3JVSzMEoB?= NWnV[I53OjZyNEi5PFU>
RBMECs MYjGeY5kfGmxbjDBd5NigQ>? NFnLbFY2yqEQvF2= NEDJRlEyKGh? NXLXO|Z2cW6qaXLpeJMhTU2DUD3JTU1qdmS3Y3XkJIlv[WO2aY\heIlwdiCxZjDSZZAyyqB? NIDZSXUzPjB2NE[2Ny=>
EndoC-βH1 NGr4OphHfW6ldHnvckBCe3OjeR?= MVm1xsDPxE1? MVSxJIg> MVHwc5RmdnSrYYTld{BodHWlb4PlMYlv\HWlZXSgbY5{fWyrbjDz[YNz\XSrb36gbY4hfGinIIDy[ZNmdmOnIH;mJIdtfWOxc3W= NInHdI0zPjB{OEW2Ni=>
EndoC-βH1 NGLRVpFHfW6ldHnvckBCe3OjeR?= M325O|XDqM7:TR?= M1nIc|EhcA>? MlXKcIVi\HNidH:gZUB{fHKxbnegZ2FOWCCrbnPy[YF{\Q>? MWSyOlAzQDV4Mh?=
SH-SY5Y NEXRbo9HfW6ldHnvckBCe3OjeR?= MWWzNEDPxE1? NH;L[pY{OCCvaX6= MV\EUXNQ NWjNT5hHe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKGGldHn2ZZRqd25ib3[gVGtC NFjXT5kzPjB{NUGzOy=>
PC-3 M2HsWGZ2dmO2aX;uJGF{e2G7 Ml\3OFAhyrWP M4XOUVIhcA>? NGj3d3ZFVVOR M17iXIxm[WS|IITvJHBROkFiYXP0bZZifGmxbh?= MXmyOlAzOzh|Nh?=
PC-3 NH\2W49E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYe0NEDDvU1? MXyyOE81QC95MjDo NFrNWW5FVVOR MkHR[IVkemWjc3XzJINmdGxidnnhZoltcXS7IITpcYUh\GWyZX7k[Y51dHl? M2jDRVI3ODJ|OEO2
SCG NGTlOldHfW6ldHnvckBCe3OjeR?= NUezVJlXOjBizszNxsA> MU\EUXNQ NWXjeItMemW4ZYLzbYJtgSC|dYDwdoV{e2W|IFnLWkB4cXSqIHGgTWM2OCCxZjCyOE41KM7:TR?= MYeyOVk3OjF|Mh?=
HEK-293 MlPMSpVv[3Srb36gRZN{[Xl? NWfKb5VjOzVizszNxsA> M16y[mROW09? NVPNclRTcW6mdXPld{BiKGOxboPwbYN2d3W|IPMAoIlv[WO2aY\heIlwduLCnTDv[kB1cGViS4[yMlEh[3W{cnXueC=> MXqyOVk3OjF|Mh?=
SCG MX3GeY5kfGmxbjDBd5NigQ>? NF\a[pMyODBizszNxsA> M4G2bmROW09? Mkm1doVlfWOnczD0bIUh\XilaYThZoltcXS7IH;mJHNETyCwZYXyc45{ Mmj5NlU6PjJzM{K=
PCCL3 MorySpVv[3Srb36gRZN{[Xl? MXqxNEDDvU1? M4LLV|I1KGh? M2fXfYVvcGGwY3XzJGR2V3h{IIDyc41wfGW{IITyZY5{[3KrcITpc44h[WO2aY\peJnDqOLCix?= NXv4c2JROjV7NkC5OVY>
3T3-L1 preadipocytes MnXBSpVv[3Srb36gRZN{[Xl? MonHNVAh|ryPwrC= M2nDXFEzKGh? NHrQcJlqdmS3Y3XzJGNTTUJicHjvd5Bpd3K7bHH0bY9vKGGwZDDDM2VDWM7{IHX4dJJme3Orb36= MnnBNlU6OjhyNUi=
H295R  MWrGeY5kfGmxbjDBd5NigQ>? Mm\yNVDDqM7:TR?= MonTOFjDqGh? MUjpcoNz\WG|ZYOgd5Rmem:rZDDt[ZRi[m:uaYTld{BqdiC2aHWgZY5lem:pZX6sJI1qdmW{YXzvMUBidmRiZ3z1Z49kd3K2aXPvbYQheGG2aIfhfZM> M2HrcVI2QDZ7NUW2
PBMC MXLGeY5kfGmxbjDBd5NigQ>? M1HMT|UxyqEQvF2= NGG0NpUzPMLiaNMg NXryeHNkcW6qaXLpeJMhfGinIHnuZ5Jm[XOnZDDz[YNz\XSrb36gc4YhXE6IIHnu[JVk\WRiYomgeIhmKESSRR?= M2\QXlI2QDZ4MEe5
GLUTag  MYHGeY5kfGmxbjDBd5NigQ>? MWqxNQKBkcL3TR?= NFjVO|cxNzJxNDDo NIPD[5J{fGmvdXzheIV{KEeOUD2xJJNm[3KndHnvckBkd3S{ZXH0[YQhf2m2aDDJRm1Z M2PjeVI2QDN{NkOx
GLUTag  MX\GeY5kfGmxbjDBd5NigQ>? M3;PXlEx6oDLwsXN NXvjNYE3PCCq M3HrOIlv[3KnYYPld{B1cGVicFPSSWIhdGW4ZXzzJJdqfGhidHjlJGlDVVh? MUKyOVg{OjZ|MR?=
BAECs NYr1PXJoTnWwY4Tpc44hSXO|YYm= M{Prd|I2KM7:TR?= MkjrNlQhcA>? NYfab|Ni\W6qYX7j[ZMhfGinIHHjeIl3[XSrb36gc4YhWFCDUt8xJIJ6KDVizszNJJJme3[ncnH0do9tNCCWNFjTMEBweiB2LWDBVC=> MV:yOVc6QDh{Nh?=
PC12 M3fCWWZ2dmO2aX;uJGF{e2G7 NYXCRZpiOjYEoN88US=> MYm0PEBp M1frWIFkfGm4YYTld{BkSU2S NXfEPHFjOjV5NkmzNFU>
GH3 Mm[wSpVv[3Srb36gRZN{[Xl? NWrrU4FKOcLizszN MYO2MYg> MnXGZZR1\W63YYTld{B1cGViY3;ydoVt[XSrb36gZoV1f2WnbjDQVmwh[W6mIFLtZYwyKGW6cILld5Nqd25? MlXwNlU4OjdyMUi=
GH3 NVvLclZLTnWwY4Tpc44hSXO|YYm= NXXHeXhFOcLizszN NFzzPZM3NWh? MYTpcoR2[2W|IGDSUEBidmRiQn3hcFEtKGK3dDDuc5QhS2yxY3usJI1TVkFiZYjwdoV{e2mxbh?= MYWyOVczPzBzOB?=
BeWo MnLXSpVv[3Srb36gRZN{[Xl? Mm\mNVDjiIsQvF5CpC=> M3vkR|czKGh? M{LT[GROW09? NXO4TXFJdWWmaXH0[ZMhSmWZbzDj[YxtKGSrZn\ldoVvfGmjdHnvci=> Mmm4NlU4OTN2MkW=
oocytes NX\R[oFtTnWwY4Tpc44hSXO|YYm= NWO5U5d[PSEQvF2= M1P1c|I1KGh? NYDtPItN[XS2ZX71ZZRmeyC{aD3pcpN2dGmwIHHjeIlwdiCxbjDvc4N6fGViR2\CSEB{cWewaX\pZ4FvfGy7wrC= MWGyOVcxPzh3NB?=
SC NITVV49HfW6ldHnvckBCe3OjeR?= M13udVAvPSEQvF2= MVOyOEBp MoPvcYlucWOtczD0bIUh\W[oZXP0JI9nKGODTWCgZY5idG:pczDvckBQOSCjbnSgUWJRKGW6cILld5Nqd25? NFSwTJMzPTdyNUi3OC=>
SC Ml\hSpVv[3Srb36gRZN{[Xl? MXywMlUh|ryP M2\JblczKGh? MVXpcoNz\WG|ZYOgZo91cCCNcn;4MVIxKGGwZDDPNUBmgHC{ZYPzbY9vKGmwIHH4c44uemWuYYTl[EBUS3NiYoX0JI9vdHliS4LvfE0zOMLi MUeyOVcxPTh5NB?=
UACC-647  MU\GeY5kfGmxbjDBd5NigQ>? NHm5XJVFVVOR M4LrN4xm[WS|IITvJIEhemm|ZTDpckBkSU2SIHzleoVteyBqRVO1NOKhRcLiMkCuN|nDqM7:TTm= M{[5b|I2PzB|MEK1
UACC-647  NUK2Xm1xTnWwY4Tpc44hSXO|YYm= NIK5eI4yOMLizszN M2\xZlE2KG2rbh?= NIXEcY1FVVOR NHrOZllqdmirYnn0d{BGWkticHjvd5Bpd3K7bHH0bY9v MkjBNlU4ODNyMkW=
UACC-647  MYjGeY5kfGmxbjDBd5NigQ>? NVvoOHZnOTEEoN88US=> NGPPbFkyPSCvaX6= Mk\JSG1UVw>? M2Pl[4lv[3KnYYPld{BmTUZ{IIDoc5NxcG:{eXzheIlwdiCuZY\lcJPDqA>? MYGyOVcxOzB{NR?=
SH-SY5Y  M4ThZmZ2dmO2aX;uJGF{e2G7 NFnCeZIyOMLizszN MVuxxsBpyqB? MWPpcoNz\WG|ZYOgUHVEKGGldHn2bZR6 MmXWNlU2QTd2M{O=
SH-SY5Y  NHztRVlHfW6ldHnvckBCe3OjeR?= NGfiTVcyOMLizszN NFvrNXMyyqCqwrC= NUHWWWV3cW6lcnXhd4V{KEGJQ{GgcXJPSSCuZY\lcC=> MlWxNlU2QTd2M{O=
hADSCs MXzGeY5kfGmxbjDBd5NigQ>? MYS15qCKyrWP MnrzN|AhdWmw MnnzbY5kemWjc3XzJINCVVBibHX2[Yx{ NGPZPZczPTV7MUmwPC=>
HEK293  Mn;HSpVv[3Srb36gRZN{[Xl? M1yzW|XjiIoEtV2= M2XsW|MxKG2rbh?= MlrkbY5kemWjc3XzJINCVVBibHX2[Yx{ NEmybZMzPTV7MUmwPC=>
3T3-L1 NGDUZ4pHfW6ldHnvckBCe3OjeR?= MlvxNk42NzVizszN M3rtWVI1KGkEoB?= MmDad4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiQWTHUEBxem:2ZXnuJIV5eHKnc4Ppc44h[XRiYXzsJIRwe2W|IITld5Rm\A>? MXyyOVU6ODV7Nx?=
OCI-Ly1  MUjGeY5kfGmxbjDBd5NigQ>? M2PublQxyqEQvF2= MnnFNeKhcMLi NV;KUHlxTE2VTx?= MnzDbY5lfWOnczD0bIUhcW6lcnXt[Y51KG:oIHPBUXAh[2:wY3XueJJifGmxboO= NH;reoMzPTV5NkKyNC=>
OCI-Ly18  MnXZSpVv[3Srb36gRZN{[Xl? NXv0elZiPDEEoN88US=> M{P2WlHDqGkEoB?= NXn0WnVsTE2VTx?= NF\1W3lqdmS3Y3XzJJRp\SCrbnPy[Y1mdnRib3[gZ2FOWCClb37j[Y51emG2aX;udy=> MVKyOVU4PjJ{MB?=
BeWo NXr5O3pFTnWwY4Tpc44hSXO|YYm= M3TlU|IxyqEEtV2= NWjZWpgxPDkEoHi= M3;kfGROW09? MmCwbY5kemWjc3XzJJRp\SCmaX\m[ZJmdnSrYYTpc44hd2ZiQnXXc{Bk\Wyucx?= NFTIfFkzPTV4Nke0NC=>
BeWo NIDRTmpHfW6ldHnvckBCe3OjeR?= M{TadFIxyqEEtV2= MoDQOFjDqGh? NHjJVFhFVVOR MlzKbY5kemWjc3XzJJRp\SCjZHjld4lwdiCxZjDUTHAuOSCvb37vZ5l1\XN? NHfYR|UzPTV4Nke0NC=>
LNCaP  MYrGeY5kfGmxbjDBd5NigQ>? NUL0VFBWOTEEoN88US=> NFTYUngyOiCqwrC= Mnv4SG1UVw>? MXrpcoR2[2W|IHGg[JJidWG2aXOgbY5kemWjc3Wgc4YhS1KHQkGgZYN1cX[rdIm= M1TTOVI2PTR6MEm5
ThGCs  MnmxSpVv[3Srb36gRZN{[Xl? M3XwSFEx6oDMzszN MVu05qCLcA>? NHf1R4ZifWevZX70d{BJUUZzQTDs[ZZmdHNidHjheEB4\XKnIIP0bY12dGG2ZXSgZpkhS2:FbEK= MWSyOVQ{OzB{Nx?=
ThGCs  M4H0R2Z2dmO2aX;uJGF{e2G7 NEO2UnEyOOLCit88US=> MoPTOQKBkmh? Mmm0bY5kemWjc3XzJGNwS2x{LXnu[JVk\WRiRVTONuKh\2WwZTDlfJBz\XO|aX;u M37hdlI2PDN|MEK3
ThGCs  M2nkUWZ2dmO2aX;uJGF{e2G7 M3LHWFEx6oDMzszN M1XZSFMhcA>? NW\YVXR4cW6qaXLpeJMhfGinIHXm[oVkfCCxZjDINm8zKG:wIFXEUlIhdVKQQR?= MonsNlU1OzNyMke=
RBMECs M{G2[mZ2dmO2aX;uJGF{e2G7 Mlq0NE4xPS9yLkWvOUDPxE1? Mni1NE4zPSCq M1fuXolv[3KnYYPld{BkSU2SIHPvcoNmdnS{YYTpc44> NIDhVnozPTRzNk[1NS=>
RBMECs MVjGeY5kfGmxbjDBd5NigQ>? MVS1xsDPxE1? M3jFdFEhcA>? NVnuU3hM[myxY3vzJJRp\SCjY4TpeoF1cW:wIH;mJHJpd0FxUl;DT{BqdmS3Y3XkJIJ6KEWPQWCtTWk> MnPtNlU1OTZ4NUG=
RBMECs NF7JPGhHfW6ldHnvckBCe3OjeR?= MV61xsDPxE1? M{nNbFEhcA>? MVXwdoV3\W62czD0bIUhTU2DUD3JTU1qdmS3Y3XkJHRGTVJidnHseYUh\GWlcnXhd4U> M3TCb|I2PDF4NkWx
RBMECs Ml;wSpVv[3Srb36gRZN{[Xl? M{C5b|XDqM7:TR?= NIe5eowyKGh? NUnISWE1eHKndnXueJMhfGinIHnuZ5Jm[XOnIHnuJGhTWCCobIX4JIFkem:|czD0bIUhSlSEIHnu[JVk\WRiYomgJGVOSVBvSVm= NH7lSZUzPTRzNk[1NS=>
RBMECs MkXkSpVv[3Srb36gRZN{[Xl? NU\KbXNFPcLizszN MlXLNUBp M1LjbolvcGmkaYTzJJRp\SCmZXPy[YF{\WRib3[gZY1wfW62IH;mJHpQNTFiaX6gUWZ{KGmwZIXj[YQh[nliRV3BVE1KUQ>? M1Xsd|I2PDF4NkWx
RBMECs NI\1OodHfW6ldHnvckBCe3OjeR?= NWOyZW5QPcLizszN NHjxVHIyKGh? MmGxdoV3\XK|ZYOgeIhmKGOqYX7n[ZMhcW5iWl:tNUBlcXO2cnnieZRqd25ic3XlckB4cXSqIFXNRXAuUUlidILlZZRu\W62 M2[4NVI2PDF4NkWx
RBMECs NV;heWlbTnWwY4Tpc44hSXO|YYm= MkT0OeKh|ryP M1znSVEhcA>? MVricI9kc3NidHjlJGVOSVBvSVmtbY5lfWOnZDDjbIFv\2ViaX6gUWxEKHCqb4PwbI9zgWyjdHnvci=> NEe1Z24zPTRzNk[1NS=>
RBMECs NGnHZ3lHfW6ldHnvckBCe3OjeR?= M2jKW|XDqM7:TR?= NWP6dWZYOSCq MUficI9kc3NidHjlJIFkfGmwIHP5eI9{c2WuZYTvckBz\WG{cnHu[4Vu\W62IIPl[Y4hf2m2aDDFUWFRNUmLIITy[YF1dWWwdNMg MViyOVQyPjZ3MR?=
Primary bovine chondrocytes NUXCdHl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVK1{txO NVL3eJptPDhiaB?= NGfsXINz\X[ncoPld{B1cGViaX7obYJqfG:{eTDl[oZm[3Rib3[gZ4Vt\WOxeHniJI9vKHC{b3zp[oVz[XSrb36gbY4h\3Kxd4ToJJBt[XSnIHPoc45lem:leYTldy=> Mn[wNlU1ODZyMU[=
EM1  NUO4T5JlTnWwY4Tpc44hSXO|YYm= MUKxOgKBks7:TR?= MYK0PEBp MlrndoVlfWOnczD0bIUh\XiycnXzd4lwdiCxZtMgUGlHyqCxctMgVHRIWzMEoHnuxsBESUyULTDvduKhTVCDQ{Ktd4lt\W6lZXSgSW0yKGOnbHzzxsA> NHLuZXczPTN5OE[2NS=>
BeWo  MVrGeY5kfGmxbjDBd5NigQ>? MVqyNOKhyrWP NVXTUmhxPDkEoHlCpC=> NVP4bHRWTE2VT9Mg NHjsSoxqdmO{ZXHz[ZMhfGinIHLleIEucEOJIILlcIVie2V? NF7FdYQzPTN4MkK2NC=>
BeWo  MV;GeY5kfGmxbjDBd5NigQ>? M{SxPFIxyqEEtV2= NFfPXlM1QMLiaNMg Mn;jSG1UV8Li NInQZmhld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBVVUWPRkG2 M3r5UlI2OzZ{Mk[w
BeWo  NWD0RoNuTnWwY4Tpc44hSXO|YYm= M3jhW|IxyqEEtV2= MWK0POKhcMLi NGSzOYxFVVORwrC= M37Q[4Rwf26{ZXf1cIF1\XNidHjlJIxmfmWuIH;mJGdEVS1z MWSyOVM3OjJ4MB?=
granulosa cells NUXXfFhWTnWwY4Tpc44hSXO|YYm= M4m0dVExKM7:TR?= MoXGNVIwOjRiaB?= M{Tmeolv[3KnYYPld{B1cGVibHX2[Yx{KG:owrDSS3MzyqCvUl7B MYeyOVM{QTFyNR?=
granulosa cells M{L2UGZ2dmO2aX;uJGF{e2G7 NFvzSGkyOCEQvF2= NX;ZWJU{OTJxMkSgbC=> NH7vTm5qdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDy[ZBwenSncjDhZ5Rqfmm2eTDmc5IhfGinIHzvcodme3RiZoLh[41mdnRiKPMIllg2PC9tMUjSS3MzNkyXQzm= NHnWVpMzPTN|OUGwOS=>
granulosa cells NWXPfotHTnWwY4Tpc44hSXO|YYm= Mkj3NVAh|ryP M2rPelI1KGh? MlLRbY5kemWjc3XzJJRp\SCrboTlcpNqfHlib3[gSG5CN3C{b4TlbY4h[2:vcHzlfC=> MoLWNlU{OzlzMEW=
granulosa cells NVr4WZpwTnWwY4Tpc44hSXO|YYm= NWrYZ2NHOTBizszN MUeyOEBp M1TlNIlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIGLHV|IheHKxbX;0[ZIh[WO2aY\peJk> NYe1V2MxOjV|M{mxNFU>
SK-N-AS  M33jdWNmdGxiVnnhZoltcXS7IFHzd4F6 NYm4VmJsOTBizszNxsA> M3vET|I1NzR6IHi= M1rTcYVvcGGwY3XzJJRqdWVvZHXw[Y5l\W62bImgZ4VtdHWuYYKgeoli[mmuaYT5xsA> MmnzNlUzPjZyNkO=
SK-N-AS  MWXGeY5kfGmxbjDBd5NigQ>? MUCxNEDPxE4EoB?= MWqyOEBp NU\rfodwcW6lcnXhd4V{KHSqZTDjRW1RKGyndnXsd:Kh NV;x[|lVOjV{Nk[wOlM>
SK-N-AS  MUDGeY5kfGmxbjDBd5NigQ>? M4jFfVExKM7:TdMg MnTkNlQhcA>? NVHH[VhGcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGO7Y3zpckBFOQ>? Mn7INlUzPjZyNkO=
SK-N-AS  Mo[2SpVv[3Srb36gRZN{[Xl? NVfqS4ZGOTBizszNxsA> M3TCcFMxKG2rbh?= M{nleIlv\HWlZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJO6zNWOjdHXubY4hMHOnck[3OUktKHBvR2PLN:6zKCi|ZYK5LUBidmRiY3;uZ49ucXSjboSgbIlocGW{IHzleoVteyCxZjDhZ5RqfmVuIIXudIhwe3Cqb4L5cIF1\WRuIN8yMYNifGWwaX6= MUKyOVI3PjB4Mx?=
SK-N-AS  NFfWV4lHfW6ldHnvckBCe3OjeR?= Mn23NVAh|ryPwrC= MWmxNE8{OC94MDDtbY4> NXzoboplcW6lcnXhd4V{KGyndnXsd{Bw\iCyLd8yMYNifGWwaX6gLJNmejZ5NTmgZY5lKGmwZIXj[ZMh[WOldX31cIF1cW:wIH;mJJAu|rJvY3H0[Y5qdiBqc3XyOlc2MSCrbjCodIVzcSmwdXPs[YFzKHKnZ3nvcpM> NX;yV5dxOjV{Nk[wOlM>
SK-N-SH NGPVbZFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2D4ZlExKM7:TdMg NG\afpA1QCCq MXzlcohidmOnczDTT{1PNVOKIH7leZJw[myjc4TvcYEh[2WubDD2bYFjcWyrdIm= MVqyOVI3PjB4Mx?=
HEK‐CFTR NV;hTXhFTnWwY4Tpc44hSXO|YYm= NX6ze|hbOuLCk{WwxsDPxE1? NXrhTmp{OC1zMjDtbY4> MXzEUXNQyqB? M4PBe4lv\HWlZYOgZUBld3On4pEQ[IVx\W6mZX70JIlw\GmmZTDl[oZtfXkEoB?= MUWyOVI3OzJyNx?=
L6 MXzGeY5kfGmxbjDBd5NigQ>? MX20NEDDvU1? NXz6XIRIOjRiaB?= NEPhUGVqdmirYnn0d{BFVUhzLXnu[JVk\WRiQXv0JIFkfGm4YYTpc44> MXiyOVI1PzV3MB?=
MIN6  NYjpZY1jTnWwY4Tpc44hSXO|YYm= NWX2OpJwOTBizszNxsA> NVnacZF2OyCq NHrUd5pqdmO{ZXHz[ZMhTDNibWLORUBmgHC{ZYPzbY9v NYnt[mc6OjV{NEGxNlQ>
ventricular cardiomyocytes  MWrGeY5kfGmxbjDBd5NigQ>? NX3RNWhHOC5yMT2xNEDPxE1? Ml36bY5kemWjc3XzJEBkSU2SIHHjZ5VufWyjdHnvci=> Mlj5NlUzODNzMUO=
ventricular cardiomyocytes  MlGzSpVv[3Srb36gRZN{[Xl? MW[wMlAyNTFyIN88US=> NGnCb|Bmfm:tZYOgZY4hcW6xdILvdIlkKHKnc4DvcpNmKDF{MNMxNVUmKGGkb4\lJIJie2GuIIfpeIgh[W5iRVO1NOKhd2ZiMj6yJOK2VQ>? M{\kPVI2OjB|MUGz
BeWo  NUfqO3p{TnWwY4Tpc44hSXO|YYm= MlG5NlAhyrWP NGj6TnM1QCCq MXPEUXNQyqB? MVzpcoR2[2W|IHPlcIwh\nW|aX;u NEG3TpQzPTF6NES3Oy=>
THP-1  NIqxPY1HfW6ldHnvckBCe3OjeR?= NEPtV2syNzFyIN88US=> NV3Qd3ZuOsLiaB?= MXLEUXNQyqB? NEjSTZZ{fXCycnXzd4V{KE2FUD2xJJBzd2S3Y4Tpc47DqA>? NHf0VY0zPTF3NEi4Ni=>
Huh-7 M1O2PGZ2dmO2aX;uJGF{e2G7 NXvDO|EyOC1{MDFOwG0> M4HGdlIhcMLi MmPXdoV{fWy2czDpckBiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKGNvTYnjJIV5eHKnc4Ppc44h[XRidHjlJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wy| MnrJNlUyODl6M{S=
C6 MoLwSpVv[3Srb36gRZN{[Xl? MojHNVAh|ryPwrC= M2DZWlIxKG2rbh?= MYfpcoNz\WG|ZYOgZ2FOWCCjY3P1cZVt[XSrb36= NWrtdnVIOjVyNkm0NVc>
SW480 NX7QOYE2TnWwY4Tpc44hSXO|YYm= MUi0NOKh|ryP MYq0POKhcA>? M3HYfWROW09? NXHXPJhC[WO2aY\heIV{KFCSMlG= MWCyOFk6PzR3MR?=
HT-29  M3fOb2Z2dmO2aX;uJGF{e2G7 MWG0NOKh|ryP NFnMepM1QMLiaB?= NFfn[5RFVVOR NXHYVWxx[WO2aY\heIV{KFCSMlG= MXuyOFk6PzR3MR?=
SW480 Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu0NOKh|ryP M3jLdVAuPzJiaB?= NUHUXGlvTE2VTx?= MoX5bY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> NEm1TpozPDl7N{S1NS=>
HT-29  MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrJ[|NuPDEEoN88US=> M3v5PFAuPzJiaB?= M{nsNmROW09? Ml3sbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> MXSyOFk6PzR3MR?=
SW480 NGm3[otHfW6ldHnvckBCe3OjeR?= MYq0NOKh|ryP MmnFO{Bl NIq4OVRFVVOR M{mzc5Jm\HWlZYOgZ49td26xc4Do[ZJmKG[xcn3heIlwdiClYYDhZoltcXS7wrC= NY\s[WFzOjR7OUe0OVE>
HT-29  NYC5ZlQ{TnWwY4Tpc44hSXO|YYm= MUC0NOKh|ryP NXvabmJwPyCm MV;EUXNQ NETQdWNz\WS3Y3XzJINwdG:wb4PwbIVz\SCob4LtZZRqd25iY3HwZYJqdGm2edMg NV3QSpZWOjR7OUe0OVE>
SW480 Ml[4RZBweHSxc3nzJGF{e2G7 M1LqVlQxyqEQvF2= NX7uS4Z6PDkEoHi= NYnRSVFUTE2VTx?= Moj0bY5lfWOnczDhckBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMz:3 MYCyOFk6PzR3MR?=
HT-29  NF7IPIJCeG:ydH;zbZMhSXO|YYm= M1v6OFQxyqEQvF2= M{e0fFQ5yqCq NFXTWWhFVVOR MVHpcoR2[2W|IHHuJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|L{e= NXrJbVVNOjR7OUe0OVE>
SW480 M3jPRWFxd3C2b4Ppd{BCe3OjeR?= M2XmfVQxyqEQvF2= NYfM[I1qPDkEoHi= M2jC[WROW09? NFHESlJqdmS3Y3XzJINp[W6pZYOgbY4hfGinIIDoc5NxcG:{eXzheIlwdiC|dHH0eZMhd2ZiUGCyRUB1[XKpZYTz MWqyOFk6PzR3MR?=
HT-29  MnLJRZBweHSxc3nzJGF{e2G7 MVW0NOKh|ryP NX;LOHdxPDkEoHi= NUDYO5hxTE2VTx?= M{Wwcolv\HWlZYOgZ4hidmenczDpckB1cGVicHjvd5Bpd3K7bHH0bY9vKHO2YYT1d{Bw\iCSUELBJJRiemendIO= MmLaNlQ6QTd2NUG=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

Protocol

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.75 mM)
Ethanol 37 mg/mL (90.13 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.5
Formula

C22H34O7

CAS No. 66575-29-9
Storage powder
in solvent
Synonyms Coleonol

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

cAMP Signaling Pathway Map

Tags: buy Forskolin | Forskolin supplier | purchase Forskolin | Forskolin cost | Forskolin manufacturer | order Forskolin | Forskolin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID